共 18 条
[1]
Keam S.J., Harper D.M., Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Ceravirx™], Drugs, 68, 3, pp. 359-372, (2008)
[2]
Cervarix suspension for injection (human papillomavirus types 16 and 18 vaccine): Summary of prescribing information
[3]
Parkin D.M., Bray F., Ferlay J., Et al., Global cancer statistics, 2002, CA Cancer J Clin, 55, 2, pp. 74-108, (2005)
[4]
Schiffman M., Castle P.E., Jeronimo J., Et al., Human papillomavirus and cervical cancer. Lancet, 370, 9590, pp. 890-907, (2007)
[5]
Munoz N., Bosch F.X., Castellsague X., Et al., Against which human papillomavirus types shall we vaccinate and screen? The international perspective, Int J Cancer, 111, 2, pp. 278-285, (2004)
[6]
Clifford G.M., Smith J.S., Plummer M., Et al., Human papillomavirus types in invasive cervical cancer worldwide: A meta-analysis, Br J Cancer, 88, 1, pp. 63-73, (2003)
[7]
Giannini S.L., Hanon E., Moris P., Et al., Enhanced humoral and memory B cellular immunity using HPV 16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only, Vaccine, 24, 33-34, pp. 5937-5949, (2006)
[8]
Paavonen J., Jenkins D., Bosch F.X., Et al., Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial, Lancet, 369, 9580, pp. 2161-2170, (2007)
[9]
Harper D.M., Franco E.L., Wheeler C., Et al., Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial, Lancet, 364, 9447, pp. 1757-1765, (2004)
[10]
Pedersen C., Petaja T., Strauss G., Et al., Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant, J Adolesc Health, 40, 6, pp. 564-571, (2007)